Brokerages Set ANI Pharmaceuticals Inc. (NASDAQ:ANIP) PT at $65.17
Shares of ANI Pharmaceuticals Inc. (NASDAQ:ANIP) have earned a consensus rating of “Buy” from the nine analysts that are covering the stock. Two analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $65.17.
Several research firms have weighed in on ANIP. Guggenheim reiterated a “buy” rating and issued a $80.00 target price (up from $65.00) on shares of ANI Pharmaceuticals in a report on Friday, August 5th. Zacks Investment Research lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. Oppenheimer Holdings Inc. boosted their target price on shares of ANI Pharmaceuticals from $65.00 to $71.00 and gave the company an “outperform” rating in a report on Friday, August 5th. TheStreet upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 26th. Finally, Citigroup Inc. lowered shares of ANI Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $49.00 target price on the stock. in a report on Friday, July 8th. They noted that the move was a valuation call.
ANI Pharmaceuticals (NASDAQ:ANIP) opened at 67.78 on Thursday. ANI Pharmaceuticals has a one year low of $26.80 and a one year high of $70.92. The stock has a market capitalization of $780.42 million, a price-to-earnings ratio of 79.65 and a beta of 2.92. The company’s 50-day moving average is $64.46 and its 200 day moving average is $54.89.
ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.34. The company had revenue of $31.30 million for the quarter, compared to analyst estimates of $27.63 million. ANI Pharmaceuticals had a net margin of 11.02% and a return on equity of 20.12%. ANI Pharmaceuticals’s revenue was up 60.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.55 EPS. Equities analysts expect that ANI Pharmaceuticals will post $4.12 EPS for the current year.
In other ANI Pharmaceuticals news, insider Arthur Przybyl sold 37,455 shares of the stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $66.97, for a total transaction of $2,508,361.35. Following the sale, the insider now directly owns 200,788 shares in the company, valued at approximately $13,446,772.36. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Robert W. Schrepfer sold 12,500 shares of the stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $67.06, for a total transaction of $838,250.00. Following the sale, the vice president now owns 17,362 shares in the company, valued at $1,164,295.72. The disclosure for this sale can be found here. 31.60% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA raised its stake in ANI Pharmaceuticals by 94.9% in the second quarter. BNP Paribas Arbitrage SA now owns 2,364 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 1,151 shares during the period. Bank of Montreal Can acquired a new stake in ANI Pharmaceuticals during the second quarter worth about $177,000. Thrivent Financial for Lutherans acquired a new stake in ANI Pharmaceuticals during the second quarter worth about $204,000. Arizona State Retirement System acquired a new stake in ANI Pharmaceuticals during the second quarter worth about $219,000. Finally, BlackRock Advisors LLC raised its stake in ANI Pharmaceuticals by 6.1% in the second quarter. BlackRock Advisors LLC now owns 3,975 shares of the specialty pharmaceutical company’s stock worth $222,000 after buying an additional 230 shares during the period. Institutional investors own 48.74% of the company’s stock.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.